Alnylam Pharmaceuticals Stock Today
| ALNY Stock | USD 245.20 3.74 1.50% |
PerformanceVery Weak
| Odds Of DistressLow
|
Alnylam Pharmaceuticals is trading at 245.20 as of the 25th of February 2025; that is 1.5 percent decrease since the beginning of the trading day. The stock's open price was 248.94. Alnylam Pharmaceuticals has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 25th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of May 2004 | Category Healthcare | Classification Health Care |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. The company has 129.46 M outstanding shares of which 2.94 M shares are presently shorted by private and institutional investors with about 4.37 trading days to cover. More on Alnylam Pharmaceuticals
Moving together with Alnylam Stock
| 0.8 | A | Agilent Technologies Earnings Call Tomorrow | PairCorr |
| 0.76 | OPT | Opthea Earnings Call Tomorrow | PairCorr |
Moving against Alnylam Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Alnylam Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | MBChB MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAlnylam Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alnylam Pharmaceuticals' financial leverage. It provides some insight into what part of Alnylam Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alnylam Pharmaceuticals (ALNY) is traded on NASDAQ Exchange in USA. It is located in 675 West Kendall Street, Cambridge, MA, United States, 02142 and employs 2,230 people. Alnylam Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 32.23 B. Alnylam Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 129.46 M outstanding shares of which 2.94 M shares are presently shorted by private and institutional investors with about 4.37 trading days to cover.
Alnylam Pharmaceuticals currently holds about 2.27 B in cash with (8.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.41.
Check Alnylam Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAlnylam Pharmaceuticals holds a total of 129.46 Million outstanding shares. The majority of Alnylam Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alnylam Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alnylam Pharmaceuticals. Please pay attention to any change in the institutional holdings of Alnylam Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that nearly one million one hundred thirty-nine thousand two hundred twenty-two invesors are currently shorting Alnylam Pharmaceuticals expressing very little confidence in its future performance.
Check Alnylam Ownership Details
Alnylam Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-12-31 | 3.4 M | |
| T. Rowe Price Associates, Inc. | 2024-12-31 | 3.3 M | |
| Norges Bank | 2024-12-31 | 2.5 M | |
| Geode Capital Management, Llc | 2024-12-31 | 2.2 M | |
| American Century Companies Inc | 2024-12-31 | 1.6 M | |
| Groupama Asset Management | 2024-12-31 | 1.5 M | |
| Orbis Allan Gray Ltd | 2024-12-31 | 1.5 M | |
| Capital Research & Mgmt Co - Division 3 | 2024-12-31 | 1.4 M | |
| Winslow Capital Management, Llc | 2024-09-30 | 961.6 K | |
| Capital World Investors | 2024-12-31 | 16.6 M | |
| Fmr Inc | 2024-12-31 | 13.5 M |
Alnylam Pharmaceuticals Historical Income Statement
Alnylam Stock Against Markets
Alnylam Pharmaceuticals Corporate Management
| Saraswathy Nochur | Equity Diversity | Profile | |
| Indrani JD | Executive Secretary | Profile | |
| Evan Lippman | Chief Officer | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Piyush JD | Chief Officer | Profile | |
| Alfred Boyle | Chief Officer | Profile | |
| Timothy Maines | Chief Officer | Profile |
Already Invested in Alnylam Pharmaceuticals?
The danger of trading Alnylam Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alnylam Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alnylam Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alnylam Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.